Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia

S. A. Zimmerman, T. A. Howard, Matthew Whorton, W. F. Rosse, A. H. James, R. E. Ware

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thrombosis may be important in the pathophysiology of certain complications of sickle cell anemia (SCA), including cerebrovascular accident (CVA, stroke) and avascular necrosis (AVN). No single laboratory or clinical parameter can accurately identify patients who will develop these thrombotic complications. We hypothesized that a subset of patients with SCA have genetic thrombophilic mutations that increase the risk of stroke or AVN. We examined nine known thrombophilic DNA polymorphisms in α-fibrinogen, β-fibrinogen, platelet glycoprotein IIIa, Factor VII, methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, prothrombin, and Factor V genes in 101 African-American patients with SCA (27 CVA, 16 AVN). The allele frequency of thrombophilic mutations ranged from 0.0 (Prothrombin, Factor V) to 0.33 (α-fibrinogen). No mutation was significantly more common in patients with CVA or AVN than in patients without these complications. These nine thrombophilic mutations do not appear to be significant risk factors for the development of clinically overt CVA or AVN in SCA.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalHematology
Volume6
Issue number5
StatePublished - 2001
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Necrosis
Stroke
Mutation
DNA
Fibrinogen
Factor V
Prothrombin
Integrin beta3
Methylenetetrahydrofolate Reductase (NADPH2)
Factor VII
Plasminogen Activator Inhibitor 1
Gene Frequency
African Americans
Thrombosis
Genes

Keywords

  • Avascular necrosis
  • Sickle cell anemia
  • Stroke
  • Thrombophilic mutations
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Zimmerman, S. A., Howard, T. A., Whorton, M., Rosse, W. F., James, A. H., & Ware, R. E. (2001). Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia. Hematology, 6(5), 347-353.

Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia. / Zimmerman, S. A.; Howard, T. A.; Whorton, Matthew; Rosse, W. F.; James, A. H.; Ware, R. E.

In: Hematology, Vol. 6, No. 5, 2001, p. 347-353.

Research output: Contribution to journalArticle

Zimmerman, SA, Howard, TA, Whorton, M, Rosse, WF, James, AH & Ware, RE 2001, 'Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia', Hematology, vol. 6, no. 5, pp. 347-353.
Zimmerman, S. A. ; Howard, T. A. ; Whorton, Matthew ; Rosse, W. F. ; James, A. H. ; Ware, R. E. / Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia. In: Hematology. 2001 ; Vol. 6, No. 5. pp. 347-353.
@article{cf65bd172e9d4402a2350703a8d6ba8e,
title = "Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia",
abstract = "Thrombosis may be important in the pathophysiology of certain complications of sickle cell anemia (SCA), including cerebrovascular accident (CVA, stroke) and avascular necrosis (AVN). No single laboratory or clinical parameter can accurately identify patients who will develop these thrombotic complications. We hypothesized that a subset of patients with SCA have genetic thrombophilic mutations that increase the risk of stroke or AVN. We examined nine known thrombophilic DNA polymorphisms in α-fibrinogen, β-fibrinogen, platelet glycoprotein IIIa, Factor VII, methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, prothrombin, and Factor V genes in 101 African-American patients with SCA (27 CVA, 16 AVN). The allele frequency of thrombophilic mutations ranged from 0.0 (Prothrombin, Factor V) to 0.33 (α-fibrinogen). No mutation was significantly more common in patients with CVA or AVN than in patients without these complications. These nine thrombophilic mutations do not appear to be significant risk factors for the development of clinically overt CVA or AVN in SCA.",
keywords = "Avascular necrosis, Sickle cell anemia, Stroke, Thrombophilic mutations, Thrombosis",
author = "Zimmerman, {S. A.} and Howard, {T. A.} and Matthew Whorton and Rosse, {W. F.} and James, {A. H.} and Ware, {R. E.}",
year = "2001",
language = "English (US)",
volume = "6",
pages = "347--353",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Thrombophilic DNA mutations as independent risk factors for stroke and avascular necrosis in sickle cell anemia

AU - Zimmerman, S. A.

AU - Howard, T. A.

AU - Whorton, Matthew

AU - Rosse, W. F.

AU - James, A. H.

AU - Ware, R. E.

PY - 2001

Y1 - 2001

N2 - Thrombosis may be important in the pathophysiology of certain complications of sickle cell anemia (SCA), including cerebrovascular accident (CVA, stroke) and avascular necrosis (AVN). No single laboratory or clinical parameter can accurately identify patients who will develop these thrombotic complications. We hypothesized that a subset of patients with SCA have genetic thrombophilic mutations that increase the risk of stroke or AVN. We examined nine known thrombophilic DNA polymorphisms in α-fibrinogen, β-fibrinogen, platelet glycoprotein IIIa, Factor VII, methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, prothrombin, and Factor V genes in 101 African-American patients with SCA (27 CVA, 16 AVN). The allele frequency of thrombophilic mutations ranged from 0.0 (Prothrombin, Factor V) to 0.33 (α-fibrinogen). No mutation was significantly more common in patients with CVA or AVN than in patients without these complications. These nine thrombophilic mutations do not appear to be significant risk factors for the development of clinically overt CVA or AVN in SCA.

AB - Thrombosis may be important in the pathophysiology of certain complications of sickle cell anemia (SCA), including cerebrovascular accident (CVA, stroke) and avascular necrosis (AVN). No single laboratory or clinical parameter can accurately identify patients who will develop these thrombotic complications. We hypothesized that a subset of patients with SCA have genetic thrombophilic mutations that increase the risk of stroke or AVN. We examined nine known thrombophilic DNA polymorphisms in α-fibrinogen, β-fibrinogen, platelet glycoprotein IIIa, Factor VII, methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, prothrombin, and Factor V genes in 101 African-American patients with SCA (27 CVA, 16 AVN). The allele frequency of thrombophilic mutations ranged from 0.0 (Prothrombin, Factor V) to 0.33 (α-fibrinogen). No mutation was significantly more common in patients with CVA or AVN than in patients without these complications. These nine thrombophilic mutations do not appear to be significant risk factors for the development of clinically overt CVA or AVN in SCA.

KW - Avascular necrosis

KW - Sickle cell anemia

KW - Stroke

KW - Thrombophilic mutations

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0035667029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035667029&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035667029

VL - 6

SP - 347

EP - 353

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 5

ER -